Oruka Therapeutics, Inc. financial data

Symbol
ORKA on Nasdaq
Location
855 Oak Grove Ave., Suite 100, Menlo Park, CA
Fiscal year end
December 31
Latest financial report
10-Q - Q2 2025 - Aug 11, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 2.68K % -18.2%
Debt-to-equity 4.11 % -67.4%
Return On Equity -29.3 % +89.3%
Return On Assets -27.2 % +62.5%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 37.5M shares +158%
Common Stock, Shares, Outstanding 37.5M shares +158%
Entity Public Float 39.7M USD +89.8%
Common Stock, Value, Issued 37K USD +164%
Weighted Average Number of Shares Outstanding, Basic 42.1M shares +1216%
Weighted Average Number of Shares Outstanding, Diluted 42.1M shares +1216%

Income Statement

Label TTM Value / Value Unit Change %
Revenues 0 USD
Research and Development Expense 100M USD +422%
General and Administrative Expense 17.4M USD +110%
Operating Income (Loss) -118M USD -328%
Nonoperating Income (Expense) 3.86M USD
Income Tax Expense (Benefit) 0 USD
Net Income (Loss) Attributable to Parent -105M USD -292%
Earnings Per Share, Basic 2 USD/shares +93.4%
Earnings Per Share, Diluted 2 USD/shares +93.4%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 65.4M USD +96.5%
Marketable Securities, Current 263M USD
Other Assets, Current 537K USD -10.4%
Assets, Current 332M USD +882%
Property, Plant and Equipment, Net 174K USD +4250%
Operating Lease, Right-of-Use Asset 2.08M USD +25850%
Other Assets, Noncurrent 103K USD +758%
Assets 357M USD +956%
Accounts Payable, Current 571K USD +137%
Employee-related Liabilities, Current 109K USD -42.6%
Liabilities, Current 12.1M USD +853%
Operating Lease, Liability, Noncurrent 1.67M USD
Liabilities 13.8M USD +984%
Accumulated Other Comprehensive Income (Loss), Net of Tax -27K USD
Retained Earnings (Accumulated Deficit) -129M USD +33.2%
Stockholders' Equity Attributable to Parent 344M USD
Liabilities and Equity 357M USD +956%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -20.9M USD -1266%
Net Cash Provided by (Used in) Financing Activities 0 USD
Net Cash Provided by (Used in) Investing Activities 0 USD
Common Stock, Shares Authorized 545M shares +445%
Common Stock, Shares, Issued 37.5M shares +158%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -1.53M USD +4.2%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 65.4M USD +332%
Deferred Tax Assets, Valuation Allowance 21.3M USD -61.6%
Deferred Tax Assets, Gross 21.5M USD -61.3%
Operating Lease, Liability 2.33M USD +9592%
Depreciation 16K USD
Payments to Acquire Property, Plant, and Equipment 13K USD
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -24.6M USD -10.6%
Lessee, Operating Lease, Liability, to be Paid 2.82M USD +11172%
Property, Plant and Equipment, Gross 222K USD -3.06%
Operating Lease, Liability, Current 660K USD +2650%
Lessee, Operating Lease, Liability, to be Paid, Year Two 768K USD
Lessee, Operating Lease, Liability, to be Paid, Year One 822K USD
Operating Lease, Weighted Average Discount Rate, Percent 0.07 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 492K USD +49100%
Lessee, Operating Lease, Liability, to be Paid, Year Three 397K USD
Deferred Tax Assets, Operating Loss Carryforwards 2.26M USD
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 5M shares 0%
Unrecognized Tax Benefits 1.05M USD
Lessee, Operating Lease, Liability, to be Paid, Year Four 304K USD
Operating Lease, Payments 63K USD +174%
Additional Paid in Capital 470M USD
Preferred Stock, Shares Outstanding 0 shares
Deferred Tax Assets, Net of Valuation Allowance 63K USD -29.2%
Share-based Payment Arrangement, Expense 24.1M USD +2105%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%